Richard Cook on Muck Rack

Richard Cook

Leeds, London
As seen in: The Guardian, Journal of Research in Nursing, PLOS ONE, Annals of the Rheumatic Diseases, Ars Technica, Journal of Business Research, MDPI, SAGE Publishing, The Conversation, Arthritis Research & Therapy and
School of Psychology, University of Leeds.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Richard

Contact Richard, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Use of Real-World Data for Studies of Dynamic Disease Processes

|
By Richard Cook, Jerald F. Lawless, Lily Zou
| The Journal of Rheumatology Verified
4. Assessing treatment effects with RWD Contrasting RCTs and observational studies. The US Food and Drug Administration (FDA) defines RWD as “data relating to patient health status and/or the delivery of healthcare routinely collected from a variety of sources,” and RWE as “the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD.”32 The FDA documents its RWE program and lists ways in which RWE is currently being used.
Open in Who Shared Issue with article?

The Use of Real-World Data for Studies of Dynamic Disease Processes

|
By Richard Cook, Jerald F. Lawless, Lily Zou, R.J. Cook
| The Journal of Rheumatology Verified
The Use of Real-World Data for Studies of Dynamic Disease Processes Richard J. Cook, Jerald F. Lawless, Lily Zou The Journal of Rheumatology Sep 2025, jrheum.2025-0160; DOI: 10.3899/jrheum.2025-0160
Open in Who Shared Issue with article?

Group sequential analysis of marked point processes: Plasma donation trials

|
By Kecheng Li, Richard Cook
| SAGE Publishing
1. Introduction Large clinical trials are now routinely designed to incorporate interim analyses to monitor the safety and effectiveness of experimental interventions. Early termination of trials showing unexpected adverse effects of a new treatment minimizes exposure to harm, while early termination when treatments are found to be effective facilitates rapid dissemination of findings and deployment of more useful treatments to affected individuals.
Open in Who Shared Issue with article?
See all 32 licensed articles (38 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified